Your Search Returned 114 tagged news reports
As is often the case, the spin-off has been the initial winner. AbbVie has produced a total return of more than 32% in pretty quick order. Abbott has done well, but the 17% return has clearly not kept pace. AbbVie is now a concentrated pure
It's not difficult to see that the company's nutritional division has the biggest upside, which is especially true in emerging markets. The company markets 16 products for infants, 13 products for young children and adults, and three health brands
Looking for a cheap stock with name-brand power and a strong, diversified portfolio of products?...Buyer beware: This is a textbook example of why the P/E ratio, one of the fundamental numbers for valuing stocks, isn't always an investor's best
After spinning off its former pharmaceuticals division at the beginning of the year, the stock's picked up more than 13% and has shareholders smiling from ear to ear. Is it time to step back on this surging stock, considering its future will be
Here Are 3 Reasons to Consider In this video, Fool bureau chief Brenton Flynn offers three reasons why you might take a pass on Abbott Labs . The company reduced its dividend after spinning off AbbVie , which reduces its appeal to income investors.
announced in a recent press release that its catheter-based MitraClip system, used to treat mitral regurgitation, showed positive results in a trial evaluating its clinical and quality-of-life results on patients with conditions too risky for surgery.
S&P Capital IQ. *Spinoff of AbbVie makes prior comparison not meaningful...But the stock has performed well, rising about 20% over the past year after adjusting for the spun-off AbbVie. After a long wait, Abbott finally broke itself into two pieces.
Watch stocks you care about The single, easiest way to keep track of all the stocks that matter.....With all of the big pharma spinoffs and sales of underperforming or unwanted business segments recently, it seems hard to pinpoint a single major
As Brenton notes, this is the last time that investors will see combined results from these now-separate companies.
In reviewing what pharmaceutical trade publications had to say about the industry in 2012, I came across MM&M's "All-Star" winners of the year. Sanofi, for example, was MM&M's "All-Star Company of the Year." What caught my attention, however, was the